Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.

ABSTRACT:

Background

Although sorafenib is considered standard therapy for advanced hepatocellular carcinoma (HCC), actual treatments vary. We evaluated the effects of different treatment strategies on overall survival.

Methods

A retrospective study of sorafenib-treated patients with advanced HCC was conducted. The primary outcome was overall survival. Prognostic factors were analyzed using multivariate Cox-proportional hazards model.

Results

A total of 658 patients (mean age, 54.5 years; 83.3% male) were analyzed; 293, 129, and 236 patients were treated with sorafenib, a combination therapy of sorafenib and transarterial chemoembolization (TACE), and TACE followed by sorafenib, respectively. Overall, 51.2% of patients treated under the combination strategy had portal vein inva

SUBMITTER: Ha Y 

PROVIDER: S-EPMC5342054 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature